Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 323

Sort by

Sort Order Select

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow

Palak Dave, Ling Zhang, Joseph Pierce, Sameer Andani, Jordan Rai, Mohammad Hussaini, Mary Ellen Walker, Nancy Gillis, Lynn Moscinski, Mikkael Sekeres, Amy DeZern, Eric Padron, Rami Komrokji, Issam El Naqa

Blood (2025) 146 (Supplement 1): 5642.

https://doi.org/10.1182/blood-2025-5642

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

Zhuoer Xie, Qianxing Mo, Sarah Buckley, David Sallman, Jeffrey Lancet, Michael Savona, Rami Komrokji, Mrinal Patnaik, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2025-3873

Published: 2025

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David Sallman, Eric Padron, Andrew Kuykendall, Onyee Chan, Zhuoer Xie, Alison Walker, Seongseok Yun, Samuel Reynolds, Kendra Sweet, Rami Komrokji, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2025-3853

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Rami Komrokji, Amin Azem, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Samuel Reynolds, Seongseok Yun, Alison Walker, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2025-3851

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study

Blood (2025) 146 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2025-3845

Published: 2025

Journal Articles

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

Blood (2025) 146 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2025-3840

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Ekrem Turk, Fernando Bustamante, Fatima Tuz Zahra, Yu-Han Chen, Rory Shallis, Onyee Chan, Samuel Reynolds, Alison Walker, Ling Zhang, Seongseok Yun, Jeffrey Lancet, David Sallman, Rami Komrokji, Jinming Song, Eric Padron, Gabriela Hobbs, Andrew Kuykendall, Zhuoer Xie

Blood (2025) 146 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2025-3815

Published: 2025

Journal Articles

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David Sallman, Gary Reuther, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Alison Walker, Onyee Chan, Seongseok Yun, Eric Padron, Rory Shallis, Jeffrey Lancet, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2025-3812

Published: 2025

Journal Articles

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Blood (2025) 146 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2025-2085

Published: 2025

Journal Articles

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Blood (2025) 146 (Supplement 1): 396.

https://doi.org/10.1182/blood-2025-396

Published: 2025

Journal Articles

NOXA modulates tipifarnib sensitivity in myeloid leukemia cells.

Traci Kruer, Lei Sun, Ariel Quintana, Meghan Ferrall-Fairbanks, Hannah Newman, Shengyan Xiang, Maria Balasis, Surendra Neupane, Onyee Chan, David Sallman, Rami Komrokji, Jeffrey Lancet, Said Sebti, Eric Padron

Blood (2025) 146 (Supplement 1): 6956.

https://doi.org/10.1182/blood-2025-6956

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Mapping out the impact of MAP kinase in primary myelofibrosis

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

NOXA modulates tipifarnib sensitivity in myeloid leukemia cells.

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only